Valuation: Elicio Therapeutics, Inc.

Market Cap 48.36M 42.43M 40.08M 36.52M 68.37M 4.63B 68.86M 480M 186M 2.37B 182M 178M 7.61B P/E 2026 *
-0.98x
P/E 2027 * -1.09x
Enterprise Value 48.36M 42.43M 40.08M 36.52M 68.37M 4.63B 68.86M 480M 186M 2.37B 182M 178M 7.61B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
72.98%
Yield 2026 *
-
Yield 2027 * -
1 week-1.06%
Current month-30.74%
1 month-37.25%
3 months-53.25%
6 months-82.72%
Current year-76.51%
1 week 1.81
Extreme 1.81
2.02
1 month 1.7
Extreme 1.705
3
Current year 1.7
Extreme 1.705
16
1 year 1.7
Extreme 1.705
16
3 years 1.7
Extreme 1.705
16
5 years 1.7
Extreme 1.705
24.39
10 years 1.7
Extreme 1.705
24.39
Manager TitleAgeSince
Chief Executive Officer 66 2018-09-30
Director of Finance/CFO 54 2025-03-23
Chief Tech/Sci/R&D Officer - 2025-11-18
Director TitleAgeSince
Director/Board Member 66 2018-09-30
Director/Board Member 54 2023-05-31
Chairman 71 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Free

Director

21,750 0.0828%
8/31/26 Free

Director

21,750 0.0828%
8/31/26 Free

Director

21,750 0.0828%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.06%-83.00%-78.92% 48.36M
-0.14%+4.33%+9.00%+31.64% 47.97B
-1.69%+1.48%+50.57%+34.53% 44.5B
+2.56%+7.34%+366.69%+608.26% 43.93B
+0.24%+2.85%+10.67%+94.47% 41.03B
-0.62%-1.11%+4.65%+48.91% 29.85B
-0.28%+1.07%+24.58%+155.58% 17.27B
+3.37%+9.21%+8.32% - 15.34B
-0.46%+1.20%+26.90%+42.21% 15.3B
-2.21%-4.70% - - 14.82B
Average +0.08%+2.14%+46.49%+117.08% 27.01B
Weighted average by Cap. +0.11%+2.86%+79.64%+160.23%

Financials

2026 *2027 *
Net sales - -
Net income -42.06M -36.91M -34.86M -31.77M -59.47M -4.03B -59.89M -417M -162M -2.06B -158M -155M -6.62B -52.78M -46.31M -43.74M -39.86M -74.62M -5.06B -75.15M -523M -203M -2.58B -198M -194M -8.31B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
26-09-25 US$1.840 -2.13% 165,360
26-09-24 US$1.880 +0.53% 339,768
26-09-23 US$1.870 0.00% 195,352
26-09-22 US$1.870 -2.09% 404,041
26-09-21 US$1.910 +1.06% 484,463
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.840USD
Average target price
13.67USD
Spread / Average Target
+642.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock